RAB Diagnostics
@rabdiagnostics.com
We support predictive biomarker discovery and validation for improving Antibody-Drug-Conjugate (ADC)-therapeutics in oncology using our proprietary RabCANCER platform.
RAB Diagnostics's Company Logos
RAB Diagnostics's Brand Colors
Hex Code
Color name
RGB
HSL
CMYK
#0BB4A1
Niagara
11, 180, 161
173, 88, 37
94, 0, 11, 29
#FFFFFF
White
255, 255, 255
0, 0, 100
0, 0, 0, 0
#3E3E3E
Mine Shaft
62, 62, 62
0, 0, 24
0, 0, 0, 76
About RAB Diagnostics
Rab Diagnostics is a pioneering brand in the realm of cancer treatment, specializing in the development of predictive tools for Antibody Drug Conjugates (ADCs). These targeted chemotherapies aim to deliver cancer-fighting drugs directly to cancer cells, minimizing damage to healthy tissues. With over 170 ADCs in clinical trials and 12 already approved, Rab Diagnostics is at the forefront of advancing anti-cancer treatments.
By identifying intracellular proteins that influence ADC response, Rab Diagnostics offers a novel approach to patient stratification. This tailored selection process promises to enhance treatment efficacy, reduce side effects, and optimize overall patient outcomes. Through their innovative platform and groundbreaking research, Rab Diagnostics is revolutionizing cancer therapy. Led by a team of renowned experts, including CEO Anette Weryagang and a distinguished Board of Directors, Rab Diagnostics is dedicated to improving patient care and advancing the field of oncology.
Company type
Privately Held
Year founded
2023
Company size
2-10 employees
